# Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

> **NCT02297230** · PHASE1,PHASE2 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 44 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **RADIATION:** Radiation Therapy (RT)
- **DRUG:** Capecitabine
- **DRUG:** Trastuzumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02297230
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-06
- **Primary completion:** 2014-12-02
- **Final completion:** 2014-12-02
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** PI Left Institution prior to reaching accrual goal and analyzing data.
- **Last updated:** 2018-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02297230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02297230, "Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02297230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*